Navigation Links
Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
Date:3/18/2009

BALTIMORE, March 18 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, reports its financial results for the third fiscal quarter ended January 31, 2009. Full details of the Company's financial results are available in the Company's Form 10-Q at www.championsbiotechnology.com.

Total revenues for the third quarter of fiscal 2009 increased to $1,052,175, compared to $624,940 for the same period in 2008. The Company derived its revenues from its Personalized Oncology and its Preclinical eValuation businesses.

Total operating expenses for the third fiscal quarter of 2009 were $1,696,457 compared to $319,998 for the same period of last year. Third quarter 2009 operating expenses included the following:

Research and development expenses were $435,274, compared to $0.00 for the comparable prior period in fiscal 2008. The increase of $435,274 was primarily related to the Company's effort to build its preclinical platform and drug pipeline and develop its drug, SG410. In addition, the Company incurred expenses related to its business development activities and personnel.

The costs of personalized oncology and preclinical eValuation services were $898,777 for the quarter ended January 31, 2009, as compared to $201,222 in the quarter ended January 31, 2008. The increase in personalized oncology costs relates mainly to the overall growth in the business and a $250,000 payment to fund the cost of a Personalized Vaccine(TM) program the Company entered into during the current quarter. The Personalized Vaccine program is structured such that the cost to establish the program is incurred primarily in the third and fourth quarter; if the program successfully continues i
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
2. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
3. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
4. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
5. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
7. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
8. Canadian Government Announces Funding for Leading Biotechnology Firms Project
9. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
10. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
11. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... by the National Nanotechnology Initiative (NNI) and the Oregon ... landscape of regional, state, and local (RSL) nanotechnology initiatives. ... visits on April 30 Where: Portland, Oregon ... Street, Portland, OR Who: Leaders of regional, ...
... PML Consortium, an association of pharmaceutical and biotechnology companies, ... from BioFortis to share and manage data relating to ... adverse event. Progressive multifocal leukoencephalopathy (PML) is ... immunocompromised patients. PML has been identified as a known ...
... about the disease and its overall occurrence and progression ... market. This is being exacerbated by the limited availability ... need for innovative and enhanced therapeutic and diagnostic tools ... treatment options. New analysis from Frost & ...
Cached Biology Technology:Registration now open: 2012 Regional, State, and Local Initiatives in Nanotechnology 2Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 3
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... new study published as the cover article for the April ... ) promises to give physicians new ways to reduce deadly ... cord. In the report, scientists from Columbia University, NY, detail ... cells, called astrocytes, use to handle invading viruses and to ...
... Novocell, Inc., a stem cell engineering company, today announced ... covering human definitive endoderm cells, an essential cell for ... developing for use as a cell therapy for diabetes, ... as lungs, intestine, liver, thymus and thyroid. ...
... CORVALLIS, Ore. Studies done with laboratory rats suggest that ... effect in lowering triglycerides, which along with cholesterol levels and ... cardiovascular disease. In the lab animals, supplements of lipoic ... effect were the same in humans which is not ...
Cached Biology News:West Nile virus studies show how star-shaped brain cells cope with infection 2New approach discovered to lowering triglycerides 2New approach discovered to lowering triglycerides 3
... include: Microarray hybridization chamber assembly (1 ... clamp, thumbscrew) Microarray chamber user guide ... intended to be cleaned and reused. The ... Catalog Oligo Microarray kits and all custom ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... modifications of Eagle's medium have ... formulation. The most widely used ... DME is a modification of ... that contains a higher concentration ...
Biology Products: